Table 2.
Number of Infectious Events and Acute Rejections During Each Period, q1 (1–3 Months Post-LTx), q2 (3–6 Months Post-LTx), q3 (6–12 Months Post-LTx), and q4 (12–24 Months Post-LTx)
| Type of Event | q1 | q2 | q3 | q4 |
|---|---|---|---|---|
| Fungal infections | 7 (4) | 8 (4) | 7 (1) | 2 (1) |
| Bacterial infections | 17 (13) | 17 (9) | 26 (16) | 18 (8) |
| Viral RI | 62 | 44 | 28 | 21 |
| CMV viremia | 0 | 30 (4) | 26 (1) | 5 |
| Acute rejections | 13 | 8 | 3 | 0 |
| Deaths | 2 | 4 | 5 | 8 |
| Patients at risk | 98 | 96 | 92 | 87 |
Number of severe infectious events that prompted intravenous treatment are denoted within parentheses.
Abbreviations: CMV, human cytomegalovirus; LTx, lung transplantation; RI, respiratory infections.